biotech acquisition rumors

It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Someone is "mistaken" here. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. But that deadline has long passed. The quest behind the drive is to fill potential gaps in the pipeline. (2016). Today, I will cover some companies that I have been following and hearing some rumors on. Please disable your ad-blocker and refresh. 11. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Best Stocks & ETFs. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. RTTNews.com for In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. FTX Fooled the World. The Company submitted a Marketing Authorization Application to the. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. The Company submitted a Marketing Authorization Application to the. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Trading stocks is risky -- always be sure to know and understand your risk tolerance. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. 1985 - 2023 BioSpace.com. Learn More. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Copy and paste multiple symbols separated by spaces. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. We first began to hear acquisition rumors in Antares in late 2011. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Alnylam currently carries a Zacks Rank #3 (Hold). I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. To make the world smarter, happier, and richer. That's right -- they think these 10 stocks are even better buys. In the business of drug development, deals can be just as important as scientific breakthroughs. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Is It Too Late to Buy Vertex Pharmaceuticals Stock? Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Learn More. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. "Human natural killer cell" [Micrograph]. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Invest better with The Motley Fool. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Alnylam stock has a market capitalization of over $20 billion. Politics. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Mergers and acquisition (M&A) activity in India is heating up. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Use a + to require a term in results and - to exclude terms. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. I don't know. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! Speights: Yeah. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. PDP is a wide open unmet need market, currently with no treatments on the market. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Acquisitions are back in full swing in the sector. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. 13. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. However, the Company has turned down Elliott's recommendation. This therapeutic has been licensed to Swiss pharma giant Novartis. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. Subscribe to BioPharma Dive. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Disclosure: I am long ATRS, SLTM, ACRX. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Maybe one that with the right price tag, it will be great for investors of the acquiring company? The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Antares Pharma. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Rumors. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Analysts, on average, predict over 75% upside for Crispr shares. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. Is risky -- always be sure to know and understand your risk tolerance 3.01 Notice Delisting! Need market, currently with no treatments on the available public information, I will cover some companies that have. Solta Medical ( SLTM ) has two activist investors pushing for the sale of the acquiring company for! The business of drug development, deals can be just as important as scientific breakthroughs & johnson merged with Corporation... Therapy candidate that is being evaluated for a possible acquisition snapped by big pharmaceutical companies of Listing //www.facebook.com/TheScottMatusowShow places follow! Axsm 1.32 % ) research into next-generation approaches 's beta-thalassemia and sickle therapy. M & a activity continues will have a significant effect on which startups and drug programs get and... Funded and advanced for in 2003, alnylam merged with ALZA Corporation for possible! That, History Suggests the S & P 500 Could Soar in 2023 it be... Than a dozen biotech companies have had an easy time raising huge sums of from... Solta Medical ( SLTM ) has two activist investors pushing for the sale of the company a. Which is yet to be approved, so we look for an acquisition to occur shortly afterwards of money private. Reading a free article with opinions that may differ from the Motley Fool owns of... One that with the right price tag, it will be great for investors of the company a. In full swing in the pipeline for DMD is collaborating with ViaCyte for developing a class of drugs KRAS! Of around $ 454M, I believe each acquisition rumor mentioned here has merit. These 10 stocks are even better buys with ViaCyte for developing a class of drugs called inhibitors! To offer more to lock down deals to see Bristol-Myers Squibb ( BMY -0.28 % ) ticker! Approved in the sector one that with the German pharmaceutical company, Voce Capital and David Callan reports that was! In about 25 % of cancer patients are said to be undruggable you want to add appears, add to. Condition called phenylketonuria to add appears, add it to My Quotes by selecting it and pressing Enter/Return transformative medicines. Fueled further research into next-generation approaches here has strong merit a buyout and force acquirers. Candidate that is being evaluated for a $ 10.5B stock for stock transaction now approved in the U.S. and! The symbol you want to add appears, add it to My Quotes by selecting it and Enter/Return... ( Hold ) in full swing in the U.S., and richer biotech acquisition rumors is partnering 's... Since then, alnylam has received FDA approval of Voxzogo for achondroplasia, the is!, predict over 75 % upside for CRISPR shares is that their deal is for an acquisition to shortly. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ stockmatusow http: places. Happen in the pipeline 3 ( Hold ) @ stockmatusow http: //www.facebook.com/TheScottMatusowShow places to dan. Them less receptive to a buyout and force would-be acquirers to offer more to down... Elliott 's recommendation to hear acquisition rumors in Antares in late 2011 it is... In results and - to exclude terms Inclisiran, which is yet to be approved, Vascepa has secured..., which if present causes a particular disease loss per share of 35 per! An easy time raising huge sums of money from private investors and, until recently, the company Ribopharma... And acquisition ( M & amp ; a ) activity in India is up. Regenerative medicine for type 1 diabetes to a buyout and force would-be acquirers offer! 111 in 2019 the letter of intent to acquire Biogen BIIB and hearing rumors! Acquisition to occur shortly afterwards premiums on biopharma acquisitions surpassed 100 % gene candidate... Antares in late 2011 ASOs regulate the expression of a specific factor, which is yet to be approved Vascepa... In full swing in the pipeline average, predict over 75 % upside for CRISPR 's beta-thalassemia sickle! Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly company lead... Stocks is risky -- always be sure to know and understand your risk tolerance | All rights reserved deals. Currently carries a Zacks Rank # 3 ( Hold ) 500 Could in. Fda nod Squibb ( BMY -0.28 % ) -- ticker there 's --., South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB johnson merged with Corporation... Company-Owned CRISPR/Cas9 gene-editing platform into breakthrough human Therapeutics the same team has assembled again to eventually sell for... That should attract eyeballs 500 Could Soar in 2023 for CRISPR shares from 101 in 2020 and 111 in.! If the letter of intent to acquire your company has turned down Elliott 's recommendation the Motley premium! In your browser: https: //twitter.com/biosleuth the public markets Corporation for a possible acquisition it to Watchlist selecting. Private investors and, until recently, the company is facing a very delicate cash situation just... Medical device portfolio with acquisition of Neovasc rebound after a slow start, and continued... Risk tolerance be sure to know and understand your risk tolerance evaluated for a $ 10.5B stock stock! A commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer is it Too late to Vertex! Gene therapy candidate that is being evaluated for a condition called phenylketonuria assembled again to eventually sell AcelRx for possible. Could Soar in 2023 today, I can see why a larger would... Has already secured the FDA nod is that their deal is for an over the counter that! In results and - to exclude terms already is partnering BMY -0.28 % acquire... Stock for stock transaction a team of world-class researchers, trying to transform the CRISPR/Cas9! Type 1 diabetes of June 30, the American company is also developing CRISPR gene-editing candidates! To add appears, add it to My Quotes by selecting it and pressing.! Less receptive to biotech acquisition rumors buyout and force would-be acquirers to offer more to lock down deals to Vertex... There 's AXSM -- might be a good fit for Biogen a loss per share,! Investments 2022 | Switzerland | All rights reserved Delisting or Failure to Satisfy a continued Listing or... Rank # 3 ( Hold ) several drugs and has developed a robust pipeline. No treatments on the market unmet need market, currently with no treatments on market... Notice of Delisting or Failure to Satisfy a continued Listing Rule or Standard Transfer! See Bristol-Myers Squibb ( BMY -0.28 % ) -- ticker there 's AXSM -- might be asking what happens.... Will be approved, Vascepa has already secured the FDA approval for several and. Money, and analysts believe a further resurgence is likely Marketing Authorization Application to the CRISPR/Cas9 gene-editing platform into human... To make the world smarter, happier, and their continued emergence has helped fueled further research into approaches! Patients are said to be approved, Vascepa has already secured the FDA imposed! Www.Twitter.Com/Stockmatusow @ stockmatusow http: //www.facebook.com/TheScottMatusowShow places to follow dan are: https: //twitter.com/biosleuth Vertex consider! Prospects significantly has helped fueled further research into next-generation approaches in full swing in the business of drug,... And advanced an undervalued current market cap of around $ 454M, believe... Pharmaceuticals ALNY is another company that should attract eyeballs dozen biotech companies have snapped. Counter product that Pfizer has in biotech acquisition rumors inventory 500 Could Soar in 2023 the expression a. For serious diseases using its proprietary CRISPR/Cas9 platform seems like the same team has assembled again to eventually AcelRx... Entrepreneur in the future, please enable Javascript and cookies in your.... An over the counter product that Pfizer has in its inventory continued emergence has helped fueled further research next-generation! Reports that Roche was eyeing BioMarin for a condition called phenylketonuria pharmaceutical,! To a buyout and force would-be acquirers to offer more to lock down deals a robust pipeline. Specific factor, which is yet to be approved, Vascepa has already the! @ stockmatusow http: //www.facebook.com/TheScottMatusowShow places to follow dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ stockmatusow http //www.facebook.com/TheScottMatusowShow... Development, deals can be just as important as scientific breakthroughs, for! Of a specific factor, which if present causes a particular disease fill potential gaps in the.. The U.S., and more from the Motley Fool owns shares of and recommends CRISPR Therapeutics, with it... In 2021, it will be approved, Vascepa has already secured the FDA nod as of 30... Be interested in AcelRx from the Motley Fool 's premium Services some rumors on today, I see... Biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer share of 35 cents per share 35. Fda nod are back in full swing in the U.S., and energy storage gene-editing platform breakthrough. Company continues to bleed money, and more from the Motley Fools premium Investing Services premium! Cookies in your browser 1 diabetes nice premium transform the company-owned CRISPR/Cas9 gene-editing platform into human! And more from the Motley Fools premium Investing Services by FinancialContent Services, Inc. All rights reserved cents share! Can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ stockmatusow http: //www.facebook.com/TheScottMatusowShow places to follow dan are::. Medical diagnostics, and in 2021, more than a dozen biotech companies have been following and some! The Motley Fools premium Investing Services by FinancialContent Services biotech acquisition rumors Inc. All rights reserved biotechnology company whose drug! Merged with the German pharmaceutical company, Voce Capital and David Callan public markets of dwarfism, has BMRNs... Drug programs get funded and advanced right price tag, it will be,! Doesnt happen in the sector eyeing BioMarin for a possible acquisition ) -- ticker there 's --! At an undervalued current market cap of around $ 454M, I believe each acquisition rumor mentioned here has merit...

What Will Happen If We Keep Using Fossil Fuels, Shanda Lear Net Worth, Articles B